Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Autonomix Medical, Inc. Common Stock (AMIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: AMIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.6
1 Year Target Price $6.6
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.76M USD | Price to earnings Ratio - | 1Y Target Price 6.6 |
Price to earnings Ratio - | 1Y Target Price 6.6 | ||
Volume (30-day avg) 2 | Beta - | 52 Weeks Range 1.09 - 19.00 | Updated Date 08/13/2025 |
52 Weeks Range 1.09 - 19.00 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -75.39% | Return on Equity (TTM) -145.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4934129 | Price to Sales(TTM) - |
Enterprise Value -4934129 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 5049890 | Shares Floating 2362129 |
Shares Outstanding 5049890 | Shares Floating 2362129 | ||
Percent Insiders 8.28 | Percent Institutions 8.72 |
Upturn AI SWOT
Autonomix Medical, Inc. Common Stock
Company Overview
History and Background
Autonomix Medical, Inc. is a medical technology company focused on improving outcomes for patients undergoing surgical and therapeutic procedures. Their focus is on developing innovative technologies to enhance the precision and safety of these procedures. The company's history is relatively recent, with a focus on novel approaches to nerve stimulation and blocking.
Core Business Areas
- Bioelectric Intermodulation (BIM) technology: Autonomix Medical's core technology platform aimed at targeting nerve interventions. It focuses on improving the safety and efficacy of procedures by guiding therapy delivery and reducing off-target effects.
Leadership and Structure
Information on Autonomix Medical's leadership team and organizational structure can be found in their SEC filings and on their website.
Top Products and Market Share
Key Offerings
- Autonomic Modulation System (AMS): Autonomix Medical is developing an AMS. It is too early to have market share or competitors as it's under development.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth fueled by technological advancements, an aging population, and increasing demand for minimally invasive procedures. The neuromodulation market is a significant segment, focusing on devices that stimulate or block nerves to treat various conditions.
Positioning
Autonomix Medical aims to be a leader in targeted nerve intervention technologies, leveraging its unique BIM technology to offer more precise and effective solutions. This technology can differentiate it from competitors using traditional nerve stimulation or ablation methods.
Total Addressable Market (TAM)
The TAM for neuromodulation and targeted nerve intervention is substantial, estimated to be in the billions of dollars. Autonomix Medical is positioned to capture a share of this market with its innovative technology, contingent on regulatory approvals and successful commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary Bioelectric Intermodulation (BIM) technology
- Potential for improved precision and safety in nerve interventions
- Focus on unmet clinical needs in neuromodulation
- Experienced management team
Weaknesses
- Limited commercialized products
- Dependence on regulatory approvals
- Need for additional funding
- Limited brand recognition
Opportunities
- Expansion into new therapeutic areas
- Partnerships with larger medical device companies
- Increasing adoption of minimally invasive procedures
- Growing market for neuromodulation therapies
Threats
- Competition from established medical device companies
- Technological obsolescence
- Regulatory hurdles
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MDLZ
- ABT
- BSX
Competitive Landscape
Autonomix Medical faces competition from larger, established medical device companies with broader product portfolios and greater resources. Its competitive advantage lies in its proprietary BIM technology, which offers the potential for more precise and effective nerve interventions.
Growth Trajectory and Initiatives
Historical Growth: Autonomix Medical's historical growth is reflected in its progress in developing its technology and conducting clinical trials.
Future Projections: Future growth projections are dependent on successful regulatory approvals, commercialization of its products, and market adoption.
Recent Initiatives: Recent initiatives include ongoing clinical trials, development of its AMS platform, and securing funding.
Summary
Autonomix Medical is a developing medical technology company with a promising platform technology. The company is still in the early stages, and faces competition from larger players. Regulatory approvals and successful commercialization are crucial for future success. Growth depends on market adoption and new opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data and other information are based on available resources and estimates. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Autonomix Medical, Inc. Common Stock
Exchange NASDAQ | Headquaters The Woodlands, TX, United States | ||
IPO Launch date 2024-01-29 | President, CEO & Director Mr. Bradley Hauser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 8 | Website https://autonomix.com |
Full time employees 8 | Website https://autonomix.com | ||
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.